Clinical Trial for Ovarian Cancer (OvaRex®)

December 13, 2007 updated by: Unither Pharmaceuticals

A Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of Intravenous OvaRex® MAb-B43.13 as Post Chemotherapy Consolidation for Epithelial Carcinoma of Ovarian, Tubal or Peritoneal Origin

This study will compare the time to disease relapse between OvaRex® MAb-B43.13-treated patients and placebo-treated patients. This study will also compare assessments of survival, quality of life, immune response and safety between active and placebo groups.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

This a Phase III, double-blind, placebo-controlled, multi-center study of intravenous OvaRex® MAb-B43.13 as post-chemotherapy consolidation for epithelial carcinoma of ovarian, tubal, or peritoneal origin.

Study Type

Interventional

Enrollment

354

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Huntsville, Alabama, United States, 35801
        • Comprehensive Cancer Institute
    • Arizona
      • Phoenix, Arizona, United States, 85006
        • Western Regional Community Clinical Oncology Program
    • Arkansas
      • Little Rock, Arkansas, United States, 72205
        • Little Rock Hematology Oncology Assoc.
    • California
      • Fullerton, California, United States, 92835
        • St. Jude Medical Center
      • La Verne, California, United States, 91750
        • Wilshire Oncology Medical Group
      • Los Angeles, California, United States, 90048
        • Cedars-Sinai Medical Center
      • Los Angeles, California, United States, 90095-1740
        • UCLA School of Medicine
      • Newport Beach, California, United States, 92663
        • Gynecologic Oncology Associates
      • Orange, California, United States, 92868
        • University of California, Irvine
      • San Diego, California, United States, 92123
        • Sharp Memorial Hospital
      • Stanford, California, United States, 94305
        • Stanford University
    • Colorado
      • Denver, Colorado, United States, 80218
        • Rocky Mountain Cancer Center-Midtown
    • Connecticut
      • Farmington, Connecticut, United States, 06030
        • University of Connecticut Cancer Center
      • Torrington, Connecticut, United States, 06790
        • Northwestern Connecticut Oncology Hematology Associates, LLP
    • Florida
      • Fort Myers, Florida, United States, 33901
        • Florida Gynecologic Oncology
      • Orlando, Florida, United States, 32804
        • Florida Hospital Cancer Institute
      • Pensacola, Florida, United States, 32504
        • Pensacola Research Consultants
      • Tampa, Florida, United States, 33612-9497
        • H. Lee Moffitt Cancer Center and Research
    • Georgia
      • Augusta, Georgia, United States, 30912
        • Medical College of Georgia
    • Illinois
      • Chicago, Illinois, United States, 60637
        • The University of Chicago Hospitals
    • Indiana
      • Indianapolis, Indiana, United States, 46260
        • St. Vincent Gynecologic Oncology
      • South Bend, Indiana, United States, 46617
        • Michiana Hematology Oncology PC
    • Kentucky
      • Louisville, Kentucky, United States, 40202
        • Louisville Oncology
      • Louisville, Kentucky, United States, 40202
        • Brown Cancer Center
    • Louisiana
      • Lake Charles, Louisiana, United States, 70601
        • Lake Charles Medical Surgical Clinic
      • New Orleans, Louisiana, United States, 70115
        • Hematology and Oncology Specialists
    • Maryland
      • Baltimore, Maryland, United States, 21237-3998
        • The Harry and Jeanette Weinberg Cancer Institute
    • Massachusetts
      • Boston, Massachusetts, United States, 02111
        • New England Medical Center
    • Mississippi
      • Jackson, Mississippi, United States, 39202
        • Women's Specialty Center
    • Missouri
      • Columbia, Missouri, United States, 65203
        • Ellis Fischel Cancer Center
    • New Jersey
      • Neptune, New Jersey, United States, 07754
        • Jersey Shore Medical Center
    • New York
      • Manhasset, New York, United States, 11030
        • North Shore University Hospital
      • New York City, New York, United States, 10011
        • St. Vincent's Comprehensive Cancer Center
      • Nyack, New York, United States, 10960
        • Nyack Hospital
      • Syracuse, New York, United States, 13210
        • SUNY-HSC Syracuse, Crouse Hospital
    • North Carolina
      • Charlotte, North Carolina, United States, 28203
        • Blumenthal Cancer Center
      • Durham, North Carolina, United States, 27710
        • Duke University Medical Center
    • Ohio
      • Cleveland, Ohio, United States, 44106
        • University Hospital - Health Systems
      • Columbus, Ohio, United States, 43222
        • GYN Oncology and Pelvic Surgery Associates
      • Toledo, Ohio, United States, 43606
        • ProMedica Health Systems
      • Toledo, Ohio, United States, 43614-5809
        • Medical College of Ohio Cancer Institute
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • Oklahoma University Health Sciences Center
    • Oregon
      • Portland, Oregon, United States, 97210
        • Northwest Cancer Specialists-Northrup
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213-3180
        • Magee-Womens Hospital
    • Rhode Island
      • Providence, Rhode Island, United States, 02905
        • Brown University School of Medicine
    • South Carolina
      • Columbia, South Carolina, United States, 29203
        • South Carolina Oncology Associates
      • Greenville, South Carolina, United States, 29601
        • Gynecologic Oncology Research and Development
    • Tennessee
      • Chattanooga, Tennessee, United States, 37403
        • Chattanooga GYN Oncology
      • Memphis, Tennessee, United States, 38120
        • West Clinic, PC
    • Texas
      • Arlington, Texas, United States, 76012
        • Arlington Cancer Center
      • Austin, Texas, United States, 78705
        • Southwest Regional Cancer Center
      • Dallas, Texas, United States, 75235-9032
        • Univ. of Texas SW Medical Center at Dallas
      • Dallas, Texas, United States, 75246-2006
        • Texas Oncology, PA
      • Fort Worth, Texas, United States, 76104
        • Texas Oncology
      • Fort Worth, Texas, United States, 76104
        • The Center for Cancer and Blood Disorders
    • Utah
      • Salt Lake City, Utah, United States, 84106
        • Utah Cancer Specialists
    • Virginia
      • Charlottesville, Virginia, United States, 22908
        • University of Virginia Cancer Center
      • Norfolk, Virginia, United States, 23502
        • VA Oncology Associates
      • Roanoke, Virginia, United States, 24014
        • Carilion GYN Oncology Associates
    • Washington
      • Seattle, Washington, United States, 98104
        • Swedish Medical Center
      • Spokane, Washington, United States, 99218
        • Cancer Care Northwest
      • Vancouver, Washington, United States, 98684
        • Northwest Cancer Specialists-Vancouver

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Patients must have a histological diagnosis of epithelial adenocarcinoma of ovarian, tubal or peritoneal origin, and their disease is classified as FIGO Stage III or IV. Histological diagnosis must have been confirmed by site pathology review of slides as documented by the site investigator. These slides must be made available for sponsor review.
  • Patients must have had an elevated serum CA125 level (per reference lab normal range) measured prior to or at surgery (i.e., not later than the immediate post-surgery period when the patient is in the surgical recovery room). If a pre-surgical CA125 measurement is not available, then the patient must have had: (a) a serum CA125 level ≥100 U/mL, and (b) tumor tissue that has been demonstrated by immunohistochemical methods to express CA125.
  • Patients must have had a documented serum CA125 level ≤65 U/mL prior to the third cycle of front-line chemotherapy.
  • Patients must have had microscopic or small diameter residual disease following primary de-bulking surgical procedure.
  • Patients must have received chemotherapy that included a platinum compound and a taxane following appropriate staging procedures. Front-line treatment can include no more than 8 cycles of chemotherapy.
  • Patients must have had a complete clinical response to their front-line surgery and chemotherapy. A complete clinical response is defined as one in which the patient had a normal physical examination, no conclusive evidence of residual tumor by CT of the abdomen and pelvis, a normal chest x-ray, and a serum CA125 level at least 5 U/mL but less than 35 U/mL as measured in the pretreatment baseline laboratories by the protocol Central Lab.
  • Patients must have undergone no more than one interval de-bulking procedure.
  • Patients must receive their first dose of study medication between 4 and 12 weeks after completing their last dose of front-line chemotherapy.
  • Patients must have voluntarily agreed to participate and have signed the informed consent, and are willing to complete all study procedures.

Exclusion Criteria:

  • Patients who have received more than one prior regimen of chemotherapy. A change in chemotherapy agents is permitted during the patient's primary therapy provided that the change is considered to be part of the initial chemotherapy treatment regimen.
  • Patients with known refractory or recurrent epithelial adenocarcinoma of ovarian, tubal, or peritoneal origin requiring chemotherapy.
  • Patients who have compromised hematopoietic function (hemoglobin <8.0 g/dL; lymphocyte count <300 mm³; neutrophil count <1000 mm³; platelet count <100,000 mm³.
  • Patients with hepatic dysfunction defined as a bilirubin >1.5 times the upper normal limits, LDH, SGOT and SGPT>2 times upper limits of normal or albumin <3.5 g/dL.
  • Patients with severe renal dysfunction defined as a serum creatinine >1.6 mg/dL.
  • Patients with a known allergy to murine proteins or have had a documented anaphylactic reaction to any drug, or a known hypersensitivity to diphenhydramine or other antihistamines of similar chemical structure.
  • Patients who have contraindications to the use of pressor agents.
  • Patients being chronically treated with immunosuppressive drugs such as cyclosporin, ACTH, or systemic corticosteroids.
  • Patients who have received immunotherapy (interferons, tumor necrosis factor, other cytokines [e.g., interleukins] or biological response modifiers, or BCG vaccines) within 6 weeks of receiving their first dose of study medication. Patients who have received hemopoietic factors are acceptable.
  • Patients who have had a splenectomy.
  • Patients with uncontrolled diseases other than cancer will be excluded. Patients with chronic diseases that are well controlled (e.g., diabetes mellitus, hypertension) are eligible.
  • Patients who have a concurrent illness or chronically taking medication, which would confound the results of the study, preclude the patient from completing the study, or mask an adverse reaction.
  • Patients who have a concurrent malignancy (except non-melanoma of the skin, in situ carcinoma of cervix), unless the patient received curative treatment and has been disease free for greater than or equal to 5 years.
  • Patients receiving other investigational drugs within 30 days of enrollment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Unither Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2002

Study Completion (ACTUAL)

December 1, 2007

Study Registration Dates

First Submitted

December 5, 2002

First Submitted That Met QC Criteria

December 5, 2002

First Posted (ESTIMATE)

December 6, 2002

Study Record Updates

Last Update Posted (ESTIMATE)

December 18, 2007

Last Update Submitted That Met QC Criteria

December 13, 2007

Last Verified

June 1, 2006

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OVA-Gy-17

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ovarian Cancer

Clinical Trials on oregovomab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe